Pharmacology. The Bridge to the 21st Century. A new approach to pharmacogenomics.

DOI Web Site PubMed 21 References

Bibliographic Information

Other Title
  • 薬理学　　２１世紀への架け橋　　薬理ゲノミクスの新しい展開
  • ヤクリ ゲノミクス ノ アタラシイ テンカイ
  • 薬理学－21世紀への架け橋

Search this article

Abstract

The medicine in the 21st century will be so called “evidence based medicine” or “personalized medicine, ” based on the principle of “right drug to right patient.” Pharmacogenomics covers the entire spectrum of genes that determines drug behavior and sensitivity, and we anticipate it will bring major impact on the healthcare system as well as the drug discovery process in the near future. Three waves of genomic impact are predicted to arise as follows: The first wave will hit on existing drugs and late-phase development candidates within the next 2-3 years, aiming to minimize the risks in clinical trials (adverse events, resistance, etc.). The wave will then affect the candidate selection process in the early pre-development stage, and finally the disease gene finding to target discovery process. The driving force will be technologies such as SNPs database, differential gene expression (DGE) analysis, proteomics, serial analysis of gene expression (SAGE) and bioinformatics. This new approach of genomic discovery (so called “integrated approach”) requires knowledge on how to implement and integrate new valuable technologies from an early stage of the discovery process. The implication of SNPs, high throughput proteomics and application of structural genomics will be the key issues in the pharmacogenomics era.

Journal

References(21)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top